References
- Global Initiative for Chronic Obstructive Lung Disease IncGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD2018 [Guidelines]. 2018. Available from: http://goldcopd.org/Accessed March 28, 2018
- WheatonAGCunninghamTJFordESCroftJBCenters for Disease Control and Prevention (CDC)Employment and activity limitations among adults with chronic obstructive pulmonary disease – United States, 2013MMWR Morb Mortal Wkly Rep2015641128929525811677
- HeronMDeaths: leading causes for 2010Natl Vital Stat Rep2013626196
- GuarascioAJRaySMFinchCKSelfTHThe clinical and economic burden of chronic obstructive pulmonary disease in the USAClinicoecon Outcomes Res2013523524523818799
- MiravitllesMRiberaAUnderstanding the impact of symptoms on the burden of COPDRespir Res20171816728431503
- AgustiAHednerJMarinJMBarbéFCazzolaMRennardSNighttime symptoms: a forgotten dimension of COPDEur Respir Rev20112012118319421881146
- VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
- DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
- LipsonDABarnhartFBrealeyNOnce-daily single-inhaler Triple versus dual therapy in patients with COPDN Engl J Med20183781816711680 Epub ahead of print29668352
- LONHALA MAGNAIR (glycopyrrolate) inhalation solution [package insert]Marlborough, MASunovion Pharmaceuticals Inc2018
- KerwinEDonohueJFGoodinTTosielloRWheelerAFergusonGTEfficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trialsRespir Med201713223825028838685
- FergusonGTGoodinTTosielloRWheelerAKerwinELong-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized studyRespir Med201713225126028919143
- JonesPMiravitllesMvan der MolenTKulichKBeyond FEV1 in COPD: a review of patient-reported outcomes and their measurementInt J Chron Obstruct Pulmon Dis2012769770923093901
- SinghDMiravitllesMVogelmeierCChronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom ManagementAdv Ther201734228129927981495
- LeidyNKMurrayLTMonzBUMeasuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trialsRespir Res20141512425287629
- KardosPWorsleySSinghDRomán-RodríguezMNewbyDEMüllerováHRandomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled broncho-dilator therapy in COPDInt J Chron Obstruct Pulmon Dis2016112885289527932872
- SinghDCorradiMSpinolaMTriple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromideInt J Chron Obstruct Pulmon Dis2017122917292829062229
- FrithPAThompsonPJRatnavadivelRGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax201570651952725841237
- BremnerPRBirkRBrealeyNIsmailaASZhuCQLipsonDASingle-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority studyRespir Res20181911929370819